Tarlatamab-Imdelltra one-time treatment cost, patient medication cost and market price analysis

Tarlatamab (trade name: Imdelltra) is a new type of targeted therapy drug mainly used for the treatment of specific types of advanced solid tumors. It enables the immune system to target tumors by accurately identifying tumor-specific targets, bringing clinical efficacy while minimizing damage to normal tissues. As a new drug approved by the US FDA in May 2024, the global launch and use of talatumumab is still in its early stages. Its high research and development costs and scarcity have also directly affected the cost of medication and the cost borne by patients.

From the market price point of view, overseas talatumumab mainly has two specifications: 1mg and 10mg. The prices are about 25,000 yuan and 148,000 yuan respectively. Depending on the dose and duration of treatment required by the patient, the cost of a complete treatment can be very expensive, especially regimens requiring a dose of 10 mg. Since it is not currently on the market in China and has not been included in medical insurance reimbursement, if patients obtain the drug through overseas channels, the cost will be borne entirely by the individual, which is a considerable financial burden for ordinary patients.

In the domestic market, Talatumumab has recently submitted a marketing application. Once approved for marketing in the future, it is expected to be regularly supplied in domestic hospitals or pharmacies. It is expected that the price of the drug may still be high after it is launched, but with the advancement of localized production and market competition, the price is expected to gradually decrease. In addition, if it is included in the medical insurance catalog in the future, the proportion of patients paying out-of-pocket will be significantly reduced, thus improving accessibility and medication burden.

Overall, talatumumab is still an emerging high-priced innovative drug in China. It is expensive for patients to use and needs to be obtained through special channels. Price information in overseas markets can provide a reference for domestic patients and doctors, but the actual cost of treatment needs to be evaluated based on the specific dosage and course of treatment. With the gradual implementation of domestic marketing and medical insurance policies, the accessibility and economics of talatumumab are expected to improve, providing patients with more treatment options.

Keyword tags:

Tarlatamab, Tarlatamab, Imdelltra, treatment cost, price, marketing progress, medical insurance

Reference materials:https://www.fda.gov/drugs/resources-information-approved-drugs/tarlatamab